Maggie Shafmaster

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers.

Translational Medicine India, Inc. provides clinical research solutions. It offers a novel therapeutic with biomarkers and early stage clinical trials for researchers. The company is headquartered in Waltham, MA.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Bain & Co., Inc. provides management consulting services. It offers advisory services to the companies on their critical issues and opportunities: strategy, marketing, organization, operations, technology and mergers and acquisitions, across all industries and geographies. The company was founded in 1973 and is headquartered in Boston, MA.

MDA is the nonprofit health agency dedicated to curing muscular dystrophy, ALS and related diseases by funding worldwide research. The Association also provides comprehensive health care and support services, advocacy and education. MDA combats neuromuscular diseases through programs of worldwide research, comprehensive medical and support services, and far-reaching professional and public health education. With national headquarters in Tucson, MDA has more than 200 offices across the country, sponsors some 200 hospital-affiliated clinics and supports more than 330 research projects around the world. MDA supports more research on neuromuscular diseases than any other private-sector organization in the world. MDA scientists are in the forefront of gene therapy research and have uncovered the genetic defects responsible for several forms of muscular dystrophy, Charcot-Marie-Tooth disease, a form of amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease), childhood spinal muscular atrophy and several other neuromuscular conditions. The Association's comprehensive services program includes diagnostic and follow-up medical consultations, flu shots, support groups, MDA summer camps for youngsters, a medical equipment program, assistance with equipment repairs and resource referral. Through its national advocacy program, MDA works to make life better for people with muscular dystrophy and related muscle diseases by providing representation in matters of public policy and research advancement, nationally and internationally; and facilitating active involvement in these areas by the people it serves. MDA was created in 1950 by a group of adults with muscular dystrophy, parents of children with muscular dystrophy and a physician-scientist studying the disorder. Since its earliest days, it has been energized by its number-one volunteer and national chairman, entertainer Jerry Lewis.

Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada.

BioHouston, Inc. engages in life science and biotechnology commercialization. The firm's mission is to create an environment that will stimulate technology transfer and research commercialization, thereby generating economic wealth for the Houston region and making it a global competitor in life science commercialization. The company is headquartered in Houston, TX.

Part of Novartis AG, Novartis Pharmaceuticals is a German company that manufactures pharmaceutical products. The company is based in Basel, Germany.

ALS Society of British Columbia provides direct support to ALS patients, along with their families and caregivers. The firm's services include equipment loan program, patient transportation support, support groups, care connections program, and mobile clinics. The company is headquartered in Richmond, Canada.

Alberta Innovates BioSolutions develops bioindustrial technologies and natural products. It delivers on the potential of agriculture and forestry in areas such as: value chain sustainability, advancing the biorefinery, quality food for health, industry challenges and emerging opportunities, and prion and prion-like protein misfolding diseases. The firm aims to be a global gateway and resource for bio-based research, talent, investment and solutions. The company was founded on January 1, 2010 and is headquartered in Edmonton, Canada.

Akashi Therapeutics Inc is a clinical stage biopharmaceutical company based in Cambridge, MA with subsidiaries in the United States. The private company has been granted orphan designation for DMD in both the US and Europe. The American company's mission is to develop treatments for Duchenne muscular dystrophy and other rare pediatric diseases. Akashi is developing a cocktail of medications with the goal of transforming Duchenne from a 100% fatal, aggressive muscle-wasting disease to a chronic, manageable condition. The application of HT-100 to DMD and other fibrotic diseases is based on pioneering work by Dr. Mark Pines at the Volcani Institute. Dosing and new patient enrollment in the phase 1b/2a clinical program have been suspended. The company was founded by leading patient organizations and biotechnology industry veterans and is managed by a seasoned team of drug development experts. The company was founded by Marc B. Blaustein, Thomas C. Wicka.

TMG Biosciences LLC provides biosurveillance and biotechnology consulting services. It assists clients to execute biosurveillance and microbial detection/characterization programs and providing subject matter expertise on biotechnology instrumentation. The company is headquartered in Austin, TX.

Caprion Proteomics, Inc. provides proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. It specializes in proteomics, biomarkers, discovery, validation, services, immune monitoring, flow cytometry and elispot areas. The company was founded by Neil Cashman and Martin LeBlanc in 2000 and is headquartered in Montreal, Canada.

Camp4 Therapeutics Corp. operates as a biotechnology company. The firm discovers a treatment option for patients. The company was founded by Paulina Hill and Leonard Zon on May 20, 2016 and is headquartered in Cambridge, the United Kingdom.

Tvardi Therapeutics, Inc. develops and commercializes medicines for the treatment of diverse cancers, chronic inflammatory and fibrotic diseases. The company was founded by David J. Tweardy and Ronald A. DePinho in 2017 and is headquartered in Houston, TX.

Provectra Therapeutics, Inc. manufactures pharmaceutical products. The private company is based in Chapel Hill, NC. The company was founded by Larry Douglas Altstiel.